Thomas MBA - Calmare Therapeutics Chief Officer
Insider
Thomas MBA is Chief Officer of Calmare Therapeutics
| Age | 70 |
| Phone | 203-368-6044 |
| Web | http://www.calmaretherapeutics.com |
Calmare Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3785) % which means that it has lost $0.3785 on every $100 spent on assets. This is way below average. Calmare Therapeutics' management efficiency ratios could be used to measure how well Calmare Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Paolo Durand | Mako Mining Corp | N/A | |
| Scott Couto | Ameriprise Financial | 51 | |
| Mark Grabowski | Xponential Fitness | 45 | |
| Jesse Muoz | Mako Mining Corp | N/A | |
| Andy PGeo | Denison Mines Corp | N/A | |
| Jun Kim | Denison Mines Corp | N/A | |
| Megan Moen | Xponential Fitness | 40 | |
| W Dengler | Denison Mines Corp | 78 | |
| Gumer Alvero | Ameriprise Financial | 53 | |
| Jason Roos | Logan Ridge Finance | 46 | |
| Tamla Forney | Waste Management | 49 | |
| David JD | Logan Ridge Finance | 55 | |
| Patrick Schafer | Logan Ridge Finance | 40 | |
| PEng Eng | Denison Mines Corp | N/A | |
| Chelsea Grayson | Xponential Fitness | 49 | |
| Sarah Luna | Xponential Fitness | 37 | |
| Brenda Morris | Xponential Fitness | 55 | |
| Rafael Carrasco | Waste Management | 53 | |
| Steven Batchelor | Waste Management | 63 | |
| Rooney C | Waste Management | N/A | |
| Edward Egl | Waste Management | N/A | |
Management Performance
| Return On Asset | -0.38 |
Calmare Therapeutics Leadership Team
Elected by the shareholders, the Calmare Therapeutics' board of directors comprises two types of representatives: Calmare Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Calmare. The board's role is to monitor Calmare Therapeutics' management team and ensure that shareholders' interests are well served. Calmare Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Calmare Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Donna Mays, Mang Services | ||
| Conrad Mir, CEO and President and Director | ||
| Thomas MBA, Chief Officer | ||
| Stephen DAmato, Chief Medical Officer | ||
| William Lipford, Division Sales |
Calmare Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Calmare Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.38 | |||
| Operating Margin | (2.14) % | |||
| Current Valuation | 11.54 M | |||
| Shares Outstanding | 30.38 M | |||
| Shares Owned By Institutions | 6.92 % | |||
| Number Of Shares Shorted | 212.63 K | |||
| Price To Earning | (0.68) X | |||
| Price To Sales | 4.82 X | |||
| Revenue | 1.17 M | |||
| Gross Profit | 771.48 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Calmare Stock
If you are still planning to invest in Calmare Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Calmare Therapeutics' history and understand the potential risks before investing.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |